PARC-T-D: A Dose Ranging Study to Examine Testagen® TDS-Testosterone 5%

Sponsor

Transdermal Delivery Solutions Corp (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT01894308

Collaborator

Advanced Therapies Centre, The London Clinic (Other)

Enrollment

Location

Arms

Anticipated Duration (Months)

6.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

Condition or Disease	Intervention/Treatment	Phase
Hypogonadotropism	Drug: Testosterone Device: Pump Sprayer	Phase 2

Detailed Description

48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

48 participants

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen® TDS-Testosterone 5% in Adult Male Subjects

Anticipated Study Start Date :

Sep 1, 2022

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

Apr 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Forearm dose Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.	Drug: Testosterone 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. Device: Pump Sprayer A dose of product solution is delivered by means of a metered pump spray.
Active Comparator: Chest Dose Half of Ss will receive their dose of Testosterone on the chest.	Drug: Testosterone 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. Device: Pump Sprayer A dose of product solution is delivered by means of a metered pump spray.

Arm

Intervention/Treatment

Active Comparator: Forearm dose

Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.

Drug: Testosterone

10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.

Device: Pump Sprayer

A dose of product solution is delivered by means of a metered pump spray.

Active Comparator: Chest Dose

Half of Ss will receive their dose of Testosterone on the chest.

Drug: Testosterone

Device: Pump Sprayer

A dose of product solution is delivered by means of a metered pump spray.

Outcome Measures

Primary Outcome Measures

Dose Range Measure of serum levels of testosterone in response to varying doses [1 week]
A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone.

Secondary Outcome Measures

Dermal Safety as measured by [1 Week]
Incidence of treatment-emergent side effects.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Inclusion Criteria:

Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
18 and 75 years of age, inclusive.
The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
The subject has a body mass index (BMI) within 18-30 kg/m2.
The subject is in otherwise good health as determined by medical history and physical examination.
The subject is a non-smoker.
The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
The subject is willing and able to comply with all testing and requirements defined in the protocol.
The subject is willing and able to return to the study site for all visits.

Exclusion Criteria:

The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
The subject has had a clinically significant illness within 30 days preceding entry into this study.
The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
The subject has a Hematocrit level > 51%
The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
Subjects with an American Urological Association System Index for Prostatism score greater than 7
Subjects with a history of prostate or breast carcinoma.
Subjects with prostatic mass on screening physical examination.
Subjects with a history of significant skin disease.
Subjects with a history of sleep apnea.
Subject with a partner with a history of breast cancer.
Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
Subject whose partner is pregnant.